News >

Expert Discusses Significance of Roche/Foundation Medicine Collaboration

Christina Izzo
Published: Thursday, Jan 15, 2015

Andre Goy, MD

Andre Goy, MD

Earlier this week, Roche announced plans to acquire a majority stake in the molecular testing company Foundation Medicine for $1.03 billion to create a partnership focused on developing personalized medicine for patients with cancer.

Andre Goy, MD, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, sat down with OncLive to discuss the recent merger and what that means for the future of precision medicine.

Can you discuss the importance of precision medicine and Foundation Medicine’s role in this venture?

Foundation Medicine is one of the diagnostic companies that is using massive parallel sequencing and next-gen sequencing to try to look broadly at the genome. This is important for several reasons. The Human Genome Project has obviously had a huge impact in oncology. We now better understand the molecular diversity of cancer. Cancer is an accumulation of mutations that drive the cells to become a cancer cell, but they differ enormously from one cancer to another, even within one type of cancer.

With the progress of understanding the cancer biology, at the same time we have developed more targeted therapy and novel therapy. What is challenging is to try to identify how we match those and how we identify the best treatment for each patient. It could be regular chemotherapy or it could be novel treatment.

Foundation Medicine is one of the early diagnostic companies that have used this technology to look broadly at several hundred genes. So now their signatures are close to 600 genes that they are looking at to try to identify the landscape of a tumor. This is done, practically, out of a fraction of a tissue from the paraffin section from the original biopsy. Through the technology, it takes 2 to 3 weeks and you get a result that gives you a landscape of the predominant anomalies and the goal is to try to see if there is something that can be used as a marker of a driver of a cancer cell to use either for treatment with approved agents or for a clinical trial.

For example, lung cancer used to be “one-size-fits-all” for chemotherapy. Now, there are 14 mutations that are important to try to identify to change the treatment, so we look at the genetic defect to try to pick a novel therapy instead of chemotherapy.

For patients who have failed all standard therapies and for which there are no other approved treatments, we like to identify some of these mutations that can sometimes give us a driver that we can target with a novel therapy.

Another implication that is also important is to identify which patients are responding early on so you can pick the patient for a clinical trial and give them the right drug earlier instead of looking at all the patients.

This effort of precision medicine is very important and many diagnostic companies are looking at this to try to help oncologists make better decisions. The problem that we face is that this is still somewhat fishing for abnormalities and the yield is sometimes difficult and it’s an expensive process but there is no question this is where the field is going.

What do you think the partnership between Roche and Foundation Medicine means for community oncologists?

So now with the joint venture with Roche, which is the largest drug manufacturer of cancer drugs, this is going to be a huge push to try to identify areas for diagnostic development, to try to identify signatures, and try to characterize early on a subset of patients who can either benefit from experimental therapies or an agent that is already approved.

This is going to help, hopefully, if we can continue this effort, to develop both for standard therapy but also for novel therapies and drug development.

What do you think are the next steps for the collaboration?

When you characterize a cancer, you look at the staging, you do blood work, scans, etc, and you try to make a recommendation. So now, we are looking at the abnormalities of cancers to help make a decision but this is still not enough, given the diversity of cancer.

It is sometimes difficult to have enough tissue or to have the tissue available and when someone relapses, they are not always rebiopsied.

So what’s going to be really exciting, and one of the major benefits of this collaboration, is the ability to start moving toward the next technology, which is either going to be naked DNA or circulating tumor cells (CTCs). CTCs can be detected early on in a large number of cancers and they are obviously not very numerous, but if you can detect those cells, develop a technology that can be used in the peripheral blood, this will have a huge impact for early diagnosis of recurrence, early diagnosis in general, and for looking at responses while a patient is receiving treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication